English
Home > Products > Vibegron API

China Vibegron API Factory

We know that we only thrive if we can easily guarantee our combined cost competiveness and high-quality advantageous at the same time for Vibegron API,CAS NO:308242-62-8,Vibegron, We sincerely be expecting exchange and cooperation with you. Allow us to move forward hand in hand and accomplish win-win circumstance.
Vibegron API, We aspire to meet the demands of our customers globally. Our range of solutions and services is continuously expanding to meet customers' requirements. We welcome new and old customers from all walks of life to contact us for future business relationships and achieving mutual success!

Related Products

Hot Products

  • Hypericin

    Hypericin

    Product Name:Hypericin
    Molecular Formula:C30H16O8
    Molecular Weight:504.44
    CAS Registry Number:548-04-9
  • Dimethyl fumarate

    Dimethyl fumarate

    Product Name:Dimethyl fumarate
    Molecular Formula:C6H8O4
    Molecular Weight;144.13
    CAS Registry Number;624-49-7
  • SodiuM Methacrylate

    SodiuM Methacrylate

    Product Name:SodiuM Methacrylate
    Molecular Formula:C4H5NaO2
    Molecular Weight:108.07
    CAS Registry Number:5536-61-8
  • 5-Methyl-4,5,6,7-Tetrahydrothiazolo[5,4-c]Pyridine-2-Carboxylic acid Hydrochloride

    5-Methyl-4,5,6,7-Tetrahydrothiazolo[5,4-c]Pyridine-2-Carboxylic acid Hydrochloride

    Product ​Name:5-Methyl-4,5,6,7-Tetrahydrothiazolo[5,4-c]Pyridine-2-Carboxylic Acid Hydrochloride
    Molecular Formula:C8H10N2O2S.HCl
    Molecular Weight:234.70
    CAS NO:720720-96-7
    Usage:Edoxaban Tosylate Monohydrate
  • 1-Bicyclo[1.1.1]Pentylamine Hydrochloride

    1-Bicyclo[1.1.1]Pentylamine Hydrochloride

    Product Name:1-Bicyclo[1.1.1]Pentylamine Hydrochloride
    Molecular Formula:C5H9N.HCl
    Molecular Weight:119.59
    CAS Registry Number:22287-35-0
  • Propranolol Hydrochloride

    Propranolol Hydrochloride

    Product Name:Propranolol Hydrochloride
    Molecular Formula:C16H22ClNO2
    Molecular Weight;295.8
    CAS Registry Number;3506-09-0
  • Related Blog
  • Reviews

  • Everything You Need To Know About Active Pharmaceutical Ingredients (API In Pharma)

    Sandoo, as a professional API manufactruer in China, we produces a wide range of active pharmaceutical ingredients which can be used in the production of medicines in different applications. Our products are produced under strict procedures and cGMP (Current Good Manufacturing Practices). In addtion, we can also customize new pharmaceutical compounds for new drugs.

  • Gilteritinib Fumarate

    Sandoo Pharmaceutica is a professional pharmaceutical intermediates manufacturer. We provide good quality Gilteritinib Fumarate Cas: 1254053-43-4. Welcome and we look forward to your inquiry!

  • What are pharmaceutical intermediates?

    Pharmaceutical intermediates are fine chemical products in the production process from pharmaceutical chemical raw materials to bulk drugs or drugs. The synthesis of chemical drugs depends on high-quality pharmaceutical intermediates. This chemical, which does not require a drug production license, can be produced in ordinary chemical plants and can be used in the synthesis of drugs as long as it reaches certain grades.

  • CAS No. 144689-24-7 Olmesartan Introduction

    Olmesartan is an angiotensin II receptor blocker, widely used for the treatment of hypertension. The Renin-Angiotensin-Aldosterone System (RAAS) plays an importent role in the development and progression of many diseases such as hypertension...

  • Outsourcing of API Manufacturing – Are Strict Regulation and Quality Checks Necessary?

    API is fundamental to the modern drug manufacturing process and cutting cost should not be the only criteria that can be applied to the production of an active pharmaceutical ingredient as it can adversely affect human health if the above-mentioned regulations and practices are not followed strictly.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept